Read by QxMD icon Read

lung cancer AND nutrition* AND chemotherapy

Matthew Maddocks, Jane Hopkinson, John Conibear, Annie Reeves, Clare Shaw, Ken C H Fearon
PURPOSE OF REVIEW: Cancer cachexia is common and reduces function, treatment tolerability and quality of life. Given its multifaceted pathophysiology a multimodal approach to cachexia management is advocated for, but can be difficult to realise in practice. We use a case-based approach to highlight practical approaches to the multimodal management of cachexia for patients across the cancer trajectory. RECENT FINDINGS: Four cases with lung cancer spanning surgical resection, radical chemoradiotherapy, palliative chemotherapy and no anticancer treatment are presented...
September 15, 2016: Current Opinion in Supportive and Palliative Care
Shirin M Shallwani, Maureen J Simmonds, Goulnar Kasymjanova, Jadranka Spahija
OBJECTIVES: Our objectives were: (a) to identify predictors of change in health-related quality of life (HRQOL) in patients with advanced non-small cell lung cancer (NSCLC) undergoing chemotherapy; and (b) to characterize symptom status, nutritional status, physical performance and HRQOL in this population and to estimate the extent to which these variables change following two cycles of chemotherapy. METHODS: A secondary analysis of a longitudinal observational study of 47 patients (24 men and 23 women) with newly diagnosed advanced NSCLC receiving two cycles of first-line chemotherapy was performed...
September 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
Xiangzheng Chen, Yangping Wu, Tinghan Yang, Mingtian Wei, Yuxi Wang, Xiangbing Deng, Congcong Shen, Wenting Li, Hang Zhang, Weiyong Xu, Lantu Gou, Yong Zeng, Yonghui Zhang, Ziqiang Wang, Jinliang Yang
BACKGROUND: Cachexia has a devastating impact on survival and quality of life for many cancer patients and contributes to nearly one-third of all cancer deaths; also, it is associated with poor responses to chemotherapy and survival. A better understanding of the underlying mechanisms of cancer-associated cachexia (CAC), coupled with effective therapeutic approaches, will improve management of progressive functional impairment in cancer patients. Salidroside, a phenylpropanoid glycoside in Rhodiola rosea L, has been reported to possess potential anti-fatigue, anti-ageing, and anti-Alzheimer's disease properties...
May 2016: Journal of Cachexia, Sarcopenia and Muscle
Sehhoon Park, Seongyeol Park, Se-Hoon Lee, Beomseok Suh, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Young Whan Kim, Dae Seog Heo
Background/Aims: Pretreatment nutritional status is an important prognostic factor in patients treated with conventional cytotoxic chemotherapy. In the era of target therapies, its value is overlooked and has not been investigated. The aim of our study is to evaluate the value of nutritional status in targeted therapy. Methods: A total of 2012 patients with non-small cell lung cancer (NSCLC) were reviewed and 630 patients with activating epidermal growth factor receptor (EGFR) mutation treated with EGFR tyrosine kinase inhibitor (TKI) were enrolled for the final analysis...
March 28, 2016: Korean Journal of Internal Medicine
Jenny G Turcott, Eva Juárez-Hernández, Martha De la Torre-Vallejo, Karla Sánchez-Lara, Julissa Luvian-Morales, Oscar Arrieta
We evaluated the effects of cisplatin and paclitaxel on taste acuity and their associations with nutritional and health-related quality of life (HRQL) in patients with advanced non-small-cell lung cancer (NSCLC). Forty chemotherapy (CT)-naïve patients were assessed at baseline and after two cycles of paclitaxel and cisplatin. The taste evaluation was performed using a rinsing technique to identify detection and recognition thresholds (DT and RT) of bitter, sweet, and umami tastes. At baseline, 37.5% of the patients reported dysgeusia...
2016: Nutrition and Cancer
Lanfang Xu, Hairong Xu, Kimberly Cannavale, Olivia Sattayapiwat, Roberto Rodriguez, John H Page, Chun Chao
PURPOSE: The aim of this study is to examine treatment patterns for chemotherapy-induced anemia (CIA) between calendar periods when the changes in the US prescribing information, for erythropoiesis-stimulating agents (ESAs) took place. METHODS: Patients diagnosed with breast, lung, colorectal, ovarian, or gastric cancer (2000-2012) who developed grade 2+ CIA (hemoglobin (Hb) <10 g/dl) were identified from Kaiser Permanente Southern California Health Plan. We estimated the proportions of CIA episodes with ESA use, red blood cell (RBC) transfusion, or prescription nutritional supplements in three calendar periods: January 1, 2000-December 31, 2006 (P1), January 1, 2007-March 24, 2010 (P2), and March 25, 2010-June 30, 2013 (P3)...
July 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Nguyen Hoang Long, Sureeporn Thanasilp, Ratsiri Thato
PURPOSE: This study explored a causal model explaining fatigue in lung cancer patients currently undertaking Chemotherapy. METHOD: In this cross-sectional study, a convenience sample of 246 lung cancer patients were recruited from six Oncology centers throughout the north of Vietnam. The hypothesized model, consisting of insomnia, dyspnea, cough, anxiety, stage of disease, physical activity, nutritional status, and number of completed chemotherapy cycles, was constructed based on Piper's Integrated Fatigue Model and a review of the literature...
April 2016: European Journal of Oncology Nursing: the Official Journal of European Oncology Nursing Society
Tami Borneman
CASE STUDY  Mr. G., an 82-year-old retired European man, was diagnosed with stage 4 non-small cell lung cancer (NSCLC) and recently enrolled on a phase II clinical trial. He is married and has two adult children, who are very supportive. He and his wife described themselves as nonpracticing Catholics. He had never smoked, and there was no personal or family history of cancer. Fatigue was the main side effect from the clinical trial drugs, necessitating frequent periods of rest throughout the day and ultimately requiring dose reduction...
November 2014: Journal of the Advanced Practitioner in Oncology
Jemima T Collins, Simon Noble, John Chester, Helen E Davies, William D Evans, Jason Lester, Diane Parry, Rebecca J Pettit, Anthony Byrne
BACKGROUND: Non-small cell lung cancer (NSCLC) frequently presents in advanced stages. A significant proportion of those with reportedly good ECOG performance status (PS) fail to receive planned multidisciplinary team (MDT) treatment, often for functional reasons, but an objective decline in physical performance is not well described. Sarcopenia, or loss of muscle mass, is an integral part of cancer cachexia. However, changes in both muscle mass and physical performance may predate clinically overt cachexia, and may be present even with normal body mass index...
2015: BMC Cancer
Oscar Arrieta, Martha De la Torre-Vallejo, Diego López-Macías, David Orta, Jenny Turcott, Eleazar-Omar Macedo-Pérez, Karla Sánchez-Lara, Laura-Alejandra Ramírez-Tirado, Vickie E Baracos
BACKGROUND: The main reason for dose reduction of afatinib is gastrointestinal toxicity (GT). In a phase II study, we analyzed anthropometrical, nutritional, and biochemical factors associated with GT induced by afatinib. MATERIALS AND METHODS: Patients diagnosed with non-small cell lung cancer who progressed to prior chemotherapy received 40 mg of afatinib. Malnutrition was determined by Subjective Global Assessment, and lean body mass (LBM) was determined by computed tomography scan analysis using a pre-established Hounsfield unit threshold...
August 2015: Oncologist
Antonio Bobbio, Marco Alifano
Surgery is still the best treatment option of lung cancer but only one third of patients are operable and prognosis remains mediocre in operated patients, with the exception of initial stages. Medical treatment is fast moving toward new frontiers. New insights in the biology of cancer development led to discovery of new drugs, which are more effective as compared to conventional platinum based chemotherapy. A new approach to immunotherapy based on immune-check point represents a remarkable innovation in lung cancer treatment...
September 2015: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
David R Hill, David S Newburg
Milk represents a unique resource for translational medicine: It contains a rich pool of biologically active molecules with demonstrated clinical benefits. The ongoing characterization of the mechanistic process through which milk components promote development and immunity has revealed numerous milk-derived compounds with potential applications as clinical therapies in infectious and inflammatory disease, cancer, and other conditions. Lactoferrin is an effective antimicrobial and antiviral agent in high-risk patient populations and a potentially potent adjuvant to chemotherapy in lung cancer...
July 2015: Nutrition Reviews
Petr Illa, Marcela Tomiskova, Jana Skrickova
BACKGROUND: Malnutrition in cancer patients may be associated with poor tolerance of chemotherapy and lower response rate after oncological treatment. METHODS: Nutritional Risk Screening 2002 (NRS) adapted for oncological patients was used to assess the risk of undernutrition in a group of 188 patients with lung cancer. The risk was evaluated on a 6-point scale according to common signs of nutritional status (weight loss, body mass index, and dietary intake), tumor, and its treatment risk factors...
2015: Journal of the American College of Nutrition
Yasuaki Miyazaki, Satoru Miyazaki, Shigeo Fujita, Hajime Hirose, Satoshi Sugimoto, Toshiya Michiura, Kazuo Yamabe, Makio Nagaoka
A 64 -year-old woman was referred to our hospital with a diagnosis of advanced rectal cancer with metastases to the left supraclavicular lymph nodes and paraaortic lymph nodes. Alow anterior resection was performed because of the symptoms of ileus. Subsequently, chemotherapy consisting of XELOX with bevacizumab was initiated as the first-line regimen, over 6 courses. Asecond -line regimen of FOLFIRI with bevacizumab was selected due to multiple lung metastases and the progression to both left supraclavicular and paraaortic lymph nodes...
November 2014: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Iwona Zaporowska-Stachowiak, Lidia Gorzelińska, Maciej Sopata, Jacek Łuczak
The treatment of acute chest pain can be a challenge in palliative care. Firstly, because acute chest pain is a symptom of a paucity of diseases, which makes diagnosis difficult and time consuming, while there is also a time constraint, due to the extreme suffering of the patient. Secondly, the condition of a patient with advanced cancer disease and co-morbidities does not always allow for required diagnostic procedures. The present report describes a case of acute, severe epigastric/chest pain in a patient with dynamic disease progression, who was receiving palliative care...
March 2015: Oncology Letters
Xingsheng Wang, Hongli Han, Qi Duan, Uzair Khan, Yonghao Hu, Xiaomei Yao
AIM: Hypoalbuminemia and systemic inflammatory response (SIR) parameters are a key role in the prognosis of cancer patients. We aim to investigate the changes of serum albumin level and SIR after chemotherapy, in patients with inoperable non-small cell lung cancer (NSCLC). The hypothesis is that improved serum albumin level may be beneficial to the SIR parameters and will reduce chemotherapy-induced toxicity. PATIENTS AND METHODS: Forty-nine stage III b or stage IV inoperable NSCLC patients were divided into two groups, depending on whether albumin administration was given before chemotherapy...
October 2014: Journal of Cancer Research and Therapeutics
Yiqiao Luo, Jiang Zhu
Primary lung cancer is one of the most common malignancies. Nowadays, both its morbidity and mortality rank first, patients with lung cancer are often goes with some affiliating symptoms such as malnutrition and weight loss. The side effects of cytotoxicity during chemotherapy may lead to further deteriorate of the nutritional status and worsen the anti-tumor therapy's efficacy and the patients' quality of life. With the development of palliative treatment and the higher request of patients for quality of life, nutritional support will be an important adjunctive treatment to maintain a good nutritional status and enhance the patients' immunity during chemotherapy...
December 2014: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
İbrahim Türker, Şeref Kömürcü, Ali Arıcan, Hatice Doruk, Özgür Özyılkan, Hasan Şenol Coşkun, Dilşen Colak, Emel Üçgül Çavuşoğlu, Alper Ata, Ahmet Sezer, Havva Yeşil Çınkır, Filiz Cay Şenler, Fikret Arpacı
Although more palliative care is necessary for terminally ill cancer patients, excess investigational tests, invasive procedures, and treatments are given instead. Between November 2009 and December 2013, six hundred and twenty-four patients with end-stage cancer who were died at inpatient setting evaluated retrospectively. Patients' characteristics, sites of tumor and metastasis, tests and invasive procedures, treatments performed in the last 2 weeks before death were collected from the hospital files and analyzed...
December 2014: Medical Oncology
Carla Alberici Pastore, Silvana Paiva Orlandi, M Cristina Gonzalez
The present study aims to evaluate compliance of cancer patients to EPA-enriched supplementation at the beginning of chemotherapy, and its effects on inflammation. Gastrointestinal and lung cancer patients were randomly assigned to receive nutritional supplement enriched with 2.2 g EPA or standard isocaloric one. Supplements were introduced 72 h before the first chemotherapy and continued for 4 wk. Serum C-reactive protein was measured and its variation was analyzed according to tumor location and treatment group...
2014: Nutrition and Cancer
Isabelle Bourdel-Marchasson, Christelle Blanc-Bisson, Adélaïde Doussau, Christine Germain, Jean-Frédéric Blanc, Jérôme Dauba, Cyril Lahmar, Eric Terrebonne, Cédric Lecaille, Joël Ceccaldi, Laurent Cany, Sandrine Lavau-Denes, Nadine Houede, François Chomy, Jessica Durrieu, Pierre Soubeyran, Pierre Senesse, Geneviève Chene, Mariane Fonck
OBJECTIVE: We tested the effect of dietary advice dedicated to increase intake in older patients at risk for malnutrition during chemotherapy, versus usual care, on one-year mortality. METHOD: We conducted a multicentre, open-label interventional, stratified (centre), parallel randomised controlled trial, with a 1∶1 ratio, with two-year follow-up. Patients were aged 70 years or older treated with chemotherapy for solid tumour and at risk of malnutrition (MNA, Mini Nutritional Assessment 17-23...
2014: PloS One
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"